Smithfield Trust’s Relay Therapeutics RLAY Stock Holding History

Smithfield Trust’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,000	Closed	-$11K	–	1079
2023 Q4	$11K	Buy	+1,000	New	+$8.44K	﹤0.01%	817

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Smithfield Trust's RLAY Position: Q1 2024 in Review

Smithfield Trust sold out of Relay Therapeutics (RLAY) in Q1 2024, closing a stake of 1,000 shares — an estimated $11K sold.

Smithfield Trust first reported a position in RLAY in Q4 2023 and held it in 1 quarter. The position peaked at $11K in Q4 2023. 189 funds tracked by Wall St. Rank hold RLAY as of Q1 2024.

Smithfield Trust reported no remaining Relay Therapeutics position as of Q1 2024 after selling out during the quarter.
Smithfield Trust sold 1,000 Relay Therapeutics shares in Q1 2024, an estimated $11K.
Smithfield Trust first reported a position in Relay Therapeutics in Q4 2023 and held it in 1 quarter.
Smithfield Trust's Relay Therapeutics position peaked at $11K in Q4 2023.
189 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2024.

Based on Smithfield Trust's 13F filing for Q1 2024, filed 7 May 2024.